Navigation Links
Array BioPharma Provides NEMO Update
Date:3/19/2017

BOULDER, Colo., March 19, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that it has withdrawn from the U.S. Food and Drug Administration's (FDA) Division of Oncology Products 2 its new drug application (NDA) for binimetinib monotherapy for the treatment of NRAS-mutant melanoma, a rare, mutationally-driven subset of skin cancer.

This action was based on thorough discussions and communications with the FDA, including exploration of various paths to approval, and followed the late cycle review meeting held with the FDA on Friday, March 17, 2017.  Based on feedback from the agency, Array concluded that the clinical benefit demonstrated in the Phase 3 NEMO clinical trial would not be found sufficient to support approval of the NRAS-mutant melanoma NDA.  

Ongoing clinical trials for binimetinib will continue. This action will not impact the planned Phase 3 COLUMBUS trial NDA of binimetinib, in combination with encorafenib, for the treatment of BRAF-mutant melanoma, which remains on track for mid-2017.

About NRAS-Mutant Melanoma
Of the estimated 10,000 annual cases of metastatic melanoma in the United States, activating NRAS mutations are present in approximately 20 percent of these patients.  The presence of an NRAS mutation is a poor prognostic indicator for these patients, and treatment options for this population remain limited beyond immunotherapy.

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Seven registration studies are currently advancing related to six Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the timing of the announcement of the results of clinical trials for our proprietary and our partnered programs, the timing of the completion or initiation of further development of our wholly-owned and our partnered programs, including the timing of regulatory filings, expectations that events will occur that will result in greater value for Array, the potential for the results of ongoing preclinical and clinical trials to support regulatory approval or the marketing success of a drug candidate, our ability to partner our proprietary drug candidates for up-front fees, milestone and/or royalty payments, our future plans to progress and develop our proprietary programs, our future capital requirements and the plans of our collaborators to progress and develop programs we have licensed to them, and our plans to build a late-stage development company. These statements involve significant risks and uncertainties, including those discussed in our most recent annual report filed on Form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially-viable drugs; risks relating to the regulatory approval process for our drug candidates, which may not result in approval for our drug candidates, cause delays in development or require that we expend more resources to obtain approval than expected; risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates; the ability of our collaborators and of Array to meet objectives tied to milestones and royalties; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks associated with our dependence on third-party service providers to successfully conduct clinical trials within and outside the United States; our ability to achieve and maintain profitability and maintain sufficient cash resources; the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities; our ability to out-license our proprietary candidates on favorable terms; and our ability to attract and retain experienced scientists and management. We are providing this information as of March 19, 2017. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

CONTACT:       
Tricia Haugeto                                                  
(303) 386-1193
thaugeto@arraybiopharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/array-biopharma-provides-nemo-update-300425869.html


'/>"/>
SOURCE Array BioPharma Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. The World Market for Microarrays
2. Label-Free Array Systems Market to be Worth US$1.7 Billion by 2024: Reduced Cost and Turnaround Time to Offer Significant Opportunities, Predicts TMR
3. Biotechnology Stocks on our Radar -- Array BioPharma, PDL BioPharma, Advaxis, and TetraLogic Pharma
4. Rancho BioSciences Donates Protein Array Software to the Research Community
5. Array BioPharma Reports Financial Results For The Second Quarter Of Fiscal 2016
6. Agena Bioscience Partners with DaRui Biotech to Bring MassARRAY Technology to the Diagnostics Market in China
7. Global Biochips and Microarrays Report 2016 - Technologies, Markets and Companies Analysis & Forecasts to 2020 & 2025
8. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2016
9. Sigma-Aldrich Partners with Sanger Institute on First Arrayed Whole Genome Lentiviral CRISPR Libraries
10. Array BioPharma Names Patricia Henahan As Chief Financial Officer
11. Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... PA (PRWEB) , ... March 28, 2017 , ... ... spoke at a Marketing Roundtable on March 22 in Philadelphia. The event was ... , The Marketing Roundtable featured breakout groups and interaction with ...
(Date:3/28/2017)... WASHINGTON , March 28, 2017  (AACR17, ... single-cell sequencing during the American Association for Cancer Research ... Center in Washington, D.C. , April ... gene expression of thousands of cells at the individual ... Experts on-hand at AACR to discuss expanded ...
(Date:3/28/2017)... , March 28, 2017 Dr. ... life sciences corporation Anpac Bio-Medical Science Company ... new, international record, processing and reporting over 40,000 ... Differentiation Analysis" (CDA) liquid biopsy tests. ... Prize Laureate Summit publications, Anpac Bio,s CDA medical ...
(Date:3/28/2017)... Focus is on the ... to the scientifically intensive operations of companies in ... and industrial. In today,s pre-market research, Stock-Callers.com dedicates attention ... PTLA), OvaScience Inc. (NASDAQ: OVAS), Ocera Therapeutics Inc. ... OCUL ). Learn more about these stocks ...
Breaking Biology Technology:
(Date:3/9/2017)... , March 9, 2017 4Dx has publicly ... Lung Imaging Workshop at the University of Pennsylvania. Founder ... to deliver the latest data to world leaders in ... brings together leaders at the forefront of the industry ... imaging. "The quality of the imaging ...
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
(Date:3/2/2017)... 2, 2017 Summary This report ... Merck KGaA and its partnering interests and activities since ... Description The Partnering Deals and Alliance since 2010 ... of one of the world,s leading life sciences companies. ... purchase to ensure inclusion of the most up to ...
Breaking Biology News(10 mins):